TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22467666
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg on day 1) plus Trastuzumab (8 mg/kg on day 1 of cycle 1, 6 mg/kg on day 1 of each subsequent cycle) plus Capecitabine (1,000 mg/m2 twice daily, days 1-14) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
Study: 22467666
Drug: Bevacizumab, Trastuzumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab, Trastuzumab, and Capecitabine combination therapy.
Study: 22469621
Drug: Ganglionic blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganglionic blocker trimethaphan
Study: 22469860
Drug: 2010-11 TIV
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2010-11 TIV (1 or 2 doses)
Study: 22471422
Drug: Acupuncture treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatments
Study: 22475206
Drug: lanreotide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: lanreotide treatment for 6 months
Study: 22476856
Drug: Lapatinib 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1500 mg/day
Study: 22480772
Drug: Adalimumab induction
Normalized name: adalimumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab induction therapy (160 mg/80 mg at Weeks 0/2), followed by 40 mg every other week for up to 20 weeks (40 mg weekly for flares/non-response after Week 12)
Study: 22483738
Drug: Hypofractionated intensity-modulated
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent temozolomide (TMZ)
Study: 22484295
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccine (PCV) 7, PCV10, PCV13
Study: 22490570
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with taxane therapy (docetaxel or paclitaxel)
Study: 22490570
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with taxane therapy
Study: 22491916
Drug: Intravitreal ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ketorolac (4 mg)
Study: 22493299
Drug: Pomalidomide in
Normalized name: Product containing pomalidomide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide in combination with weekly dexamethasone (Pom/dex)
Study: 22494428
Drug: Collaborative-care management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative-care management program (pharmacotherapy and combination trials)
Study: 22494428
Drug: Collaborative-care management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative-care management program (psychotherapy and combination trials)
Study: 22496496
Drug: Furosemide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (25 mg iv infusion)
Study: 22497915
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral care without antiseptic)
Study: 22499837
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with lower and higher doses of pyrimethamine with sulfadizine
Study: 22503395
Drug: Primary surgery
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary surgery treatment (PST)
Study: 22504934
Drug: Radioimmunotherapy (RIT)
Normalized name: mumps virus vaccine live, RIT-4385 strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioimmunotherapy (RIT) using yttrium-90-ibritumomab tiuxetan at two dose levels (22 and 30 MBq/kg) combined with reduced intensity conditioning (RIC) using fludarabine, melphalan, and alemtuzumab followed by allogeneic hematopoietic cell transplantation (HCT).
Study: 22506623
Drug: Ambrisentan 5
Normalized name: ambrisentan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 5 or 10 mg once daily
Study: 22508772
Drug: apremilast (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: apremilast (both doses)
Study: 22511492
Drug: lenalidomide/dexamethasone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenalidomide/dexamethasone treatment after nine cycles
Study: 22511492
Drug: baseline (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: baseline (before treatment)
Study: 22511498
Drug: Rituximab, fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab, fludarabine and mitoxantrone followed by 2-monthly rituximab maintenance
Study: 22511498
Drug: Rituximab pharmacokinetics
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab pharmacokinetics
Study: 22512844
Drug: Focal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal therapy using high-intensity focused ultrasound delivered to all known cancer lesions with a margin of normal tissue.
Study: 22515800
Drug: 15% dextrose
Normalized name: Clinimix Sulfite Free, Amino Acids 5% with 15% Dextrose (Clinimix Sulfite-Free) intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% dextrose extra-articular injections and 25% dextrose intra-articular prolotherapy injections at 1, 5, and 9 weeks, with as-needed treatments at weeks 13 and 17.
Study: 22515800
Drug: 15% dextrose
Normalized name: Clinimix Sulfite Free, Amino Acids 5% with 15% Dextrose (Clinimix Sulfite-Free) intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% dextrose extra-articular injections and 25% dextrose intra-articular prolotherapy injections.
Study: 22515800
Drug: Low-dose opioid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose opioid analgesia for procedure-related pain.
Study: 22517904
Drug: Lenalidomide 15
Normalized name: lenalidomide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 15 mg/d and cyclophosphamide 100 mg/d (RdC)
Study: 22520270
Drug: TNFerade biologic
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFerade biologic (5 weekly injections, dose-escalated from 4 × 10(8) to 4 × 10(11) PU) combined with chemoradiotherapy (cisplatin 75 mg/m(2), 5-fluorouracil 1000 mg/m(2)/d for 96 hours, radiation therapy to 45 Gy)
Study: 22520945
Drug: Oseltamivir (30-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (30-75 mg once daily for 6 weeks)
Study: 22520945
Drug: Pooled safety
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled safety data from treatment studies (duration of 5 days) in children
Study: 22522612
Drug: Naloxone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusion during exercise (N+)
Study: 22522612
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion during exercise (N-)
Study: 22522612
Drug: Naloxone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusion without exercise (control)
Study: 22524591
Drug: TExT-MED program
Approvals — FDA: no, EMA: no, PMDA: no
Description: TExT-MED program (text message-based intervention, 3 messages daily for 3 weeks)
Study: 22525392
Drug: Alkali-treated penicillin
Normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkali-treated penicillin G
Study: 22525392
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G sodium (PGs)
Study: 22525883
Drug: certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: certolizumab pegol (CZP) 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks up to week 52
Study: 22527084
Drug: Standardised drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised drug labelling used hospital-wide
Study: 22527084
Drug: Standardised drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised drug labelling used in ICU
Study: 22527084
Drug: Standardised drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised drug labelling by region
Study: 22527084
Drug: Desire for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desire for ISO 26825 norm labelling from pharmaceutical industry
Study: 22528284
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DARB) 1 mg/kg IV immediately before surgery
Study: 22529273
Drug: Standard perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard perioperative care with intraoperative morphine
Study: 22537988
Drug: 2-dose MenC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose MenC vaccine (given at 2 and 4 months)
Study: 22537988
Drug: 1-dose MenC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-dose MenC vaccine (given at 2 months)
Study: 22537988
Drug: All subjects
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects after the 12 month MenC dose
Study: 22539091
Drug: Tasisulam sodium
Normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasisulam sodium (420 μg/mL) administered intravenously on day 1 of 21-day cycles
Study: 22540954
Drug: 2.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg/kg intravenous artesunate
Study: 22541066
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus 3-AP (96 mg/m(2) for 4 days, with cisplatin at 25 mg/m(2) on days 2 and 3)
Study: 22541066
Drug: 3-AP (96
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-AP (96 mg/m(2))
Study: 22541660
Drug: Cataract surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cataract surgery with intact posterior capsules, manual posterior capsulorrhexis without anterior limbal vitrectomy, and anterior limbal vitrectomy
Study: 22542159
Drug: Systemic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic infusion of bone marrow mesenchymal stem cells (BMMSCs)
Study: 22543217
Drug: Adaptive planning
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adaptive planning (replanning of radiation therapy)
Study: 22543217
Drug: Nonadaptive planning
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nonadaptive planning (original treatment plans)
Study: 22546242
Drug: Ezatiostat 2000
Normalized name: Ezatiostat
DrugBank: Ezatiostat (DB05460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezatiostat 2000 mg/day + Lenalidomide 10 mg (days 1-21 of a 28-day cycle)
Study: 22546242
Drug: Ezatiostat 2500
Normalized name: Ezatiostat
DrugBank: Ezatiostat (DB05460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezatiostat 2500 mg/day + Lenalidomide 10 mg (days 1-21 of a 28-day cycle)
Study: 22547163
Drug: Salirasib 200-800
Normalized name: Salirasib
DrugBank: Salirasib (DB12681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salirasib 200-800 mg orally (PO) twice daily (bid) for 21 days every 28 days in combination with gemcitabine.
Study: 22547163
Drug: Salirasib administered
Normalized name: Salirasib
DrugBank: Salirasib (DB12681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salirasib administered alone and in combination with gemcitabine.
Study: 22547163
Drug: Gemcitabine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (standard dose schedule).
Study: 22550086
Drug: Amantadine sulfate
Normalized name: amantadine sulfate
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine sulfate 6.3 ± 0.87 mg/kg/d for 8 weeks
Study: 22554343
Drug: IRIS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRIS plus bevacizumab (S-1 40-60 mg twice daily on Days 1 to 14, irinotecan 100 mg/m² and bevacizumab 5 mg/kg on Days 1 and 15 of a 28-day cycle)
Study: 22555973
Drug: Intravenous carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous carfilzomib 20 mg/m(2) for all treatment cycles (Cohort 1)
Study: 22555973
Drug: Intravenous carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous carfilzomib 20 mg/m(2) for cycle 1 and then 27 mg/m(2) for all subsequent cycles (Cohort 2)
Study: 22556318
Drug: QuantiFERON TB
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QuantiFERON TB Gold In-Tube assay (QFT-GIT) monthly for 1 year
Study: 22558101
Drug: DOTAP:cholesterol nanoparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOTAP:cholesterol nanoparticles encapsulating a TUSC2 expression plasmid (DOTAP:chol-TUSC2) administered intravenously every 3 weeks at escalating doses (0.01 to 0.09 mg/kg)
Study: 22559192
Drug: Low-frequency deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency deep TMS (1 Hz for 10 min) applied over the left temporoparietal cortex, 10 daily treatment sessions at 110% of the motor threshold.
Study: 22559192
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (placebo) according to patient randomization.
Study: 22560543
Drug: High-dose thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thoracic radiation (61.2 Gy over 5 weeks, daily 1.8-Gy fractions on days 1-22, then twice-daily 1.8-Gy fractions on days 23-33) with concurrent chemotherapy (Cisplatin 60 mg/m² IV on day 1, Etoposide 120 mg/m² IV on days 1-3 and days 22-24).
Study: 22560543
Drug: High-dose thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thoracic radiation with concurrent chemotherapy.
Study: 22563089
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m(2) infused weekly on days 56, 63, 70, and 77 after transplantation)
Study: 22565291
Drug: Intrapartum antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapartum antibiotic prophylaxis (10.5% of women received this intervention)
Study: 22565291
Drug: Low birth
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low birth weight (<1500 g)
Study: 22566506
Drug: Tacrolimus (0.15-0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (0.15-0.30 mg/kg per day in 2 divided oral doses) and prednisone (60 mg per day, tapered off during 1 to 4 weeks)
Study: 22566605
Drug: Decitabine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine (20 mg/m² intravenously on days 1-10) plus bortezomib (escalated up to the target 1.3 mg/m² on days 5, 8, 12, and 15)
Study: 22566747
Drug: High-adherence insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-adherence insulin
Study: 22568777
Drug: DIGS software
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIGS software insulin dosage adjustments
Study: 22570147
Drug: Efatutazone at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efatutazone at doses ranging from 0.10 to 1.15 mg PO twice daily for 6 weeks
Study: 22570147
Drug: Efatutazone at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efatutazone at the recommended phase 2 dose of 0.5 mg PO twice daily
Study: 22573483
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of RAAS blockade and diuretics
Study: 22573483
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or more diuretics
Study: 22573483
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with diuretics and RAAS blockade
Study: 22574715
Drug: In-patient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-patient treatment program based on physical exercise and a balanced diet
Study: 22576338
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI regimen (irinotecan 180 mg/m² i.v. on day 1, leucovorin 200 mg/m² i.v. on days 1 and 2, 5-FU 400 mg/m² i.v. bolus on days 1 and 2, and 5-FU 600 mg/m² i.v. by ci for 22 h on days 1 and 2, repeated every 2 weeks)
Study: 22577154
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) treatment
Study: 22579160
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with tapering and discontinuation of risperidone long-acting injection over 6 weeks, followed by reinstitution of oral risperidone or risperidone long-acting injection upon symptom recurrence.
Study: 22579160
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group not explicitly mentioned, but refers to the absence of continuous treatment after 2 years.
Study: 22580120
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation therapy (54 Gy, 5-fluouracil-based)
Study: 22583335
Drug: Rilonacept (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept (320 mg loading dose followed by 160 mg weekly for up to 1 year)
Study: 22586008
Drug: Laxative-free computed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative-free computed tomographic colonography (CTC)
Study: 22589436
Drug: Oral minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral minocycline 100 mg twice daily for 6 months
Study: 22590502
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg DNA
Study: 22590502
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg DNA
Study: 22590502
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg DNA
Study: 22592608
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Study: 22592608
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of blinatumomab
Study: 23643595
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of copeptin and cTnI
Study: 22594491
Drug: GRAZAX(®) (Phleum
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRAZAX(®) (Phleum Pratense, 75,000 SQ-T/2,800 BAU), administered as one tablet daily for at least 4 months before the pollen season and maintained throughout the season.
Study: 22595848
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation therapy followed by total mesorectal excision
Study: 22599356
Drug: Targeted hypoglossal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted hypoglossal neurostimulation (THN) therapy with the aura6000™ System
Study: 22605616
Drug: Tivantinib (ARQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib (ARQ 197) 120, 240, 360, and 480 mg BID plus erlotinib 150 mg QD
Study: 22605616
Drug: Tivantinib (ARQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib (ARQ 197) 360 mg BID plus erlotinib 150 mg QD
Study: 22605650
Drug: Tivantinib 120
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib 120 mg orally twice daily, then 360 mg twice daily per protocol amendment
Study: 22608106
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 μg BID
Study: 22608261
Drug: Individualised accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised accelerated radiotherapy (INDAR) with a mean lung dose (MLD) of 19 Gy, spinal cord 54 Gy, brachial plexus 66 Gy, central structures 74 Gy, total dose between 51 and 69 Gy delivered in 1.5 Gy BID up to 45 Gy followed by 2 Gy QD, starting at the 2nd or 3rd course of chemotherapy
Study: 22608338
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg twice daily (recommended phase 2 dose)
Study: 22608338
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg twice daily (in patients with Val600Glu BRAF-mutant melanoma)
Study: 22608338
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg twice daily (in patients with Val600 BRAF-mutant melanoma)
Study: 22615311
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 30-μg 2009 Novartis pH1N1 monovalent vaccine (Fluvirin)
Study: 22615311
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of double-strength pH1N1 vaccine
Study: 22615340
Drug: Biological antiplatelet
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological antiplatelet drug responsiveness (specific and aggregation-based assays)
Study: 22619884
Drug: Resistance prevalence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance prevalence for other antibiotics
Study: 22621246
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation (fish oil capsules providing 1.14g DHA and 1.56g EPA for 12 weeks)
Study: 22622425
Drug: Anti-IL-17 receptor
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-IL-17 receptor antibody AMG 827
Study: 22622497
Drug: At-home short
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-home short daily hemodialysis (6 times per week)
Study: 22623056
Drug: Quality control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality control samples at 0.0600, 2.00 and 8.00 ng/mL
Study: 22626819
Drug: Intraoperative PAI-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative PAI-1 (plasminogen activator inhibitor-1)
Study: 22627182
Drug: Pitavastatin 4
Normalized name: PITAVASTATIN 4MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 4 mg alone
Study: 22627182
Drug: Pitavastatin 4
Normalized name: PITAVASTATIN 4MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 4 mg with lopinavir/ritonavir 400 mg/100 mg